Efficacy and safety of tralokinumab in adolescents with moderate-to- severe atopic dermatitis: results of the phase 3 ECZTRA 6 trial

Main Article Content

Amy Paller
Andrew Blauvelt
Weily Soong
Shinichi Imafuku
Chih-ho Hong
Marie Schuttelaar
Petra Amoudruz
Azra Kurbasic
Lise Soldbro
Katja Lophaven
Michael Cork
Anthony Bewley
Eric Simpson

Keywords

atopic dermatitis

Abstract

N/A

References

1. Marciniak J. Acta Derm Venereol. 2017;97(6):711–714. doi: 10.2340/00015555-2633.

2. Ricci G. Dermatol Reports.
2011;4(1):e1. doi: 10.4081/dr.2012.e1.

3. Slattery M. J Allergy Clin Immunol. 2011; 128(3):668–671.e3. doi:
10.1016/j.jaci.2011.05.003.

4. Halvorsen J. J Invest Dermatol. 2014;134(7):1847–1854. doi: 10.1038/jid.2014.70.

5. Bieber T.
Allergy. 2020;75(1):54-62. doi: 10.1111/all.13954.

6. Furue K et al. Immunology. 2019; 158(4): 281-286. doi: 10.1111/imm.13120.


7. Szegedi K et al. JEADV. 2015;29(11):2136–2144. doi: 10.1111/jdv.13160.

8. Tsoi LC et al. J Invest Dermatol.
2019;139(7):1480-1489. doi: 10.1016/j.jid.2018.12.018.

9. Popovic B et al. J Mol Biol. 2017; 429(2): 208–219. doi:

10.1016/j.jmb.2016.12.005. 10. Wollenberg A. Br J Dermatol. 2021; 184(3):437–449. doi: 10.1111/bjd.19574.

Most read articles by the same author(s)

1 2 3 4 5 6 7 8 > >>